Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease
Status:
Recruiting
Trial end date:
2024-09-12
Target enrollment:
Participant gender:
Summary
The study is a Phase II clinical trial. Patients will receive intensity modulated total body
irradiation (TBI) at a dose of 3 Gy with standard fludarabine/ i.v. cyclophosphamide
conditioning prior to human leukocyte antigen (HLA)-haploidentical hematopoietic stem cell
transplant (HSCT).
The primary objective of the study is to determine the engraftment at Day +60 following
HLA-haploidentical hematopoietic stem cell transplant protocol using immunosuppressive agents
and low-dose total body irradiation (TBI) for conditioning and post-transplant
cyclophosphamide in patients with sickle cell disease.